ÂÜÀòÂÒÂ×

Linda Robertson ’80, Ph.D. is currently an independent consultant providing strategic expertise in international biologic and small molecule drug development, including personalized medicine. She has more than 20 years of management experience in pharmaceutical regulatory affairs in large global pharmaceutical, and small biotechnology companies, and startups. Her business career has been based on strong problem-solving skills derived from her initial scientific training and applied to key leadership roles in the entrepreneurial world of biotechnology.

Dr. Robertson embarked on consulting after serving as the Vice President of Regulatory Affairs at Ignyta, Inc., a biotechnology company focused on the development of molecularly targeted cancer therapies. Ignyta was acquired in December 2017 by Roche Pharmaceuticals, a world leader in personalized medicine. Prior to Ignyta, Dr. Robertson served as Vice President of Regulatory Affairs and Quality Assurance at Intercept Pharmaceuticals where she led the approval of Ocaliva® for the treatment of rare, life-threatening liver disease.